[Pathophysiological conditions progressing from impaired glucose tolerance: coronary artery disease (ischemic heart disease)].
Tomono
Shoichi
S
School of Health Sciences, Faculty of Medicine, Gunma University.
Uchiyama
Tsuyoshi
T
Ohyama
Yoshio
Y
D020909:Acarbose / Q000627:therapeutic use; D003510:Cyclohexanes / Q000627:therapeutic use; D005215:Fasting / Q000097:blood; D018149:Glucose Intolerance / Q000150:complications* / Q000453:epidemiology / Q000628:therapy; D017127:Glycation End Products, Advanced / Q000096:biosynthesis; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000628:therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008019:Life Style; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077205:Pioglitazone; D019518:Postprandial Period; D011493:Protein Kinase C / Q000378:metabolism; D045162:Thiazolidinediones / Q000627:therapeutic use
D003510:Cyclohexanes; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077715:Nateglinide; D010649:Phenylalanine; D011493:Protein Kinase C; D020909:Acarbose; D000077205:Pioglitazone